Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price objective hoisted by Leerink Swann from $141.00 to $146.00 in a research note published on Friday. They currently have an outperform rating on the medical equipment provider’s stock. Leerink Swann also issued estimates for Zimmer Biomet Holdings’ Q3 2017 earnings at $1.76 EPS, Q4 2017 earnings at $2.27 EPS, FY2017 earnings at $8.24 EPS, FY2018 earnings at $8.83 EPS and FY2019 earnings at $9.60 EPS.

Several other equities research analysts have also recently commented on ZBH. Cantor Fitzgerald set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a hold rating in a research note on Thursday, July 27th. Canaccord Genuity cut Zimmer Biomet Holdings from a buy rating to a hold rating and decreased their target price for the stock from $141.00 to $135.00 in a research note on Friday. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a buy rating in a research note on Friday. Piper Jaffray Companies reissued a buy rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday. Finally, Stifel Nicolaus reissued a hold rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings has a consensus rating of Buy and a consensus price target of $137.76.

Zimmer Biomet Holdings (NYSE ZBH) opened at 121.32 on Friday. The stock’s 50 day moving average price is $127.79 and its 200 day moving average price is $121.35. The company has a market cap of $24.48 billion, a PE ratio of 34.55 and a beta of 1.21. Zimmer Biomet Holdings has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same period in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. Equities research analysts anticipate that Zimmer Biomet Holdings will post $8.36 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/leerink-swann-boosts-zimmer-biomet-holdings-inc-nysezbh-price-target-to-146-00/1465040.html.

The company also recently announced a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 23rd were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Chad F. Phipps sold 6,200 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ZBH. MARSHALL WACE ASIA Ltd bought a new position in shares of Zimmer Biomet Holdings during the first quarter valued at $38,621,000. Cibc World Markets Corp boosted its position in shares of Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after buying an additional 7,269 shares during the period. Israel Discount Bank of New York bought a new position in shares of Zimmer Biomet Holdings during the first quarter valued at $721,000. Koch Industries Inc. bought a new position in shares of Zimmer Biomet Holdings during the first quarter valued at $255,000. Finally, Global X Management Co. LLC boosted its position in shares of Zimmer Biomet Holdings by 37.4% in the first quarter. Global X Management Co. LLC now owns 4,461 shares of the medical equipment provider’s stock valued at $545,000 after buying an additional 1,215 shares during the period. 84.13% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.